The SUMO pathway in pancreatic cancer: insights and inhibition

An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneeweis, Christian, Hassan, Zonera, Schick, Markus, Keller, Ulrich, Schneider, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851129/
https://www.ncbi.nlm.nih.gov/pubmed/33071285
http://dx.doi.org/10.1038/s41416-020-01119-6
_version_ 1783645580457672704
author Schneeweis, Christian
Hassan, Zonera
Schick, Markus
Keller, Ulrich
Schneider, Günter
author_facet Schneeweis, Christian
Hassan, Zonera
Schick, Markus
Keller, Ulrich
Schneider, Günter
author_sort Schneeweis, Christian
collection PubMed
description An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational modifications (PTMs) with ubiquitin-like proteins, including small ubiquitin-like modifiers (SUMOs), mediate numerous processes that can contribute to the fitness and survival of cancer cells. The contribution of SUMOylation to transcriptional control, DNA repair pathways, mitotic progression, and oncogenic signalling has been described. Here we review functions of the SUMO pathway in PDAC, with a special focus on its connection to an aggressive subtype of the disease characterised by high MYC activity, and discuss SUMOylation inhibitors under development for precise PDAC therapies.
format Online
Article
Text
id pubmed-7851129
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78511292021-02-08 The SUMO pathway in pancreatic cancer: insights and inhibition Schneeweis, Christian Hassan, Zonera Schick, Markus Keller, Ulrich Schneider, Günter Br J Cancer Review Article An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational modifications (PTMs) with ubiquitin-like proteins, including small ubiquitin-like modifiers (SUMOs), mediate numerous processes that can contribute to the fitness and survival of cancer cells. The contribution of SUMOylation to transcriptional control, DNA repair pathways, mitotic progression, and oncogenic signalling has been described. Here we review functions of the SUMO pathway in PDAC, with a special focus on its connection to an aggressive subtype of the disease characterised by high MYC activity, and discuss SUMOylation inhibitors under development for precise PDAC therapies. Nature Publishing Group UK 2020-10-19 2021-02-02 /pmc/articles/PMC7851129/ /pubmed/33071285 http://dx.doi.org/10.1038/s41416-020-01119-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Schneeweis, Christian
Hassan, Zonera
Schick, Markus
Keller, Ulrich
Schneider, Günter
The SUMO pathway in pancreatic cancer: insights and inhibition
title The SUMO pathway in pancreatic cancer: insights and inhibition
title_full The SUMO pathway in pancreatic cancer: insights and inhibition
title_fullStr The SUMO pathway in pancreatic cancer: insights and inhibition
title_full_unstemmed The SUMO pathway in pancreatic cancer: insights and inhibition
title_short The SUMO pathway in pancreatic cancer: insights and inhibition
title_sort sumo pathway in pancreatic cancer: insights and inhibition
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851129/
https://www.ncbi.nlm.nih.gov/pubmed/33071285
http://dx.doi.org/10.1038/s41416-020-01119-6
work_keys_str_mv AT schneeweischristian thesumopathwayinpancreaticcancerinsightsandinhibition
AT hassanzonera thesumopathwayinpancreaticcancerinsightsandinhibition
AT schickmarkus thesumopathwayinpancreaticcancerinsightsandinhibition
AT kellerulrich thesumopathwayinpancreaticcancerinsightsandinhibition
AT schneidergunter thesumopathwayinpancreaticcancerinsightsandinhibition
AT schneeweischristian sumopathwayinpancreaticcancerinsightsandinhibition
AT hassanzonera sumopathwayinpancreaticcancerinsightsandinhibition
AT schickmarkus sumopathwayinpancreaticcancerinsightsandinhibition
AT kellerulrich sumopathwayinpancreaticcancerinsightsandinhibition
AT schneidergunter sumopathwayinpancreaticcancerinsightsandinhibition

Ejemplares similares